白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
3期
159-162
,共4页
淋巴瘤,B细胞%吉西他滨%奥沙利铂
淋巴瘤,B細胞%吉西他濱%奧沙利鉑
림파류,B세포%길서타빈%오사리박
Lymphoma,B-cell%Gemcitabine,oxaliplatin
目的 探讨吉西他滨+奥沙利铂方案(GemOx方案)加或不加利妥昔单抗治疗老年人B细胞性淋巴瘤的有效性、安全性、耐受性.方法 11例经病理活组织检查证实的老年B细胞性恶性淋巴瘤患者均采用吉西他滨1000 mg/m2,第1天；奥沙利铂100 mg/m2,第1天,在吉西他滨用完后使用；使用利妥昔单抗的患者在每个疗程的第0天予利妥昔单抗375 mg/m2,21d为1个周期.治疗3～4个周期(诱导治疗结束时)和6个周期(巩固治疗结束)后评估治疗效果、不良反应.结果 11例患者平均年龄72.18岁(55 ～ 83岁).8例合并其他疾病.10例可评估患者中,诱导治疗后总体反应率(ORR)达90％(9/10),5例早期获得了完全反应/未经证实的完全反应(CR/CRu),4例初治弥漫性大B细胞淋巴瘤( DLBCL)采用GemOx+利妥昔单抗方案,早期ORR达100 ％;4例难治/复发患者采用GemOx方案,其中3例早期病情得到有效控制.所有患者均未作剂量调整,血液学不良反应可控制,无患者出现肾脏损害.无疾病进展相关死亡发生.结论 GemOx加或不加利妥昔单抗方案不良反应可控,耐受良好,是老年B细胞淋巴瘤患者可选的一线治疗方案.
目的 探討吉西他濱+奧沙利鉑方案(GemOx方案)加或不加利妥昔單抗治療老年人B細胞性淋巴瘤的有效性、安全性、耐受性.方法 11例經病理活組織檢查證實的老年B細胞性噁性淋巴瘤患者均採用吉西他濱1000 mg/m2,第1天；奧沙利鉑100 mg/m2,第1天,在吉西他濱用完後使用；使用利妥昔單抗的患者在每箇療程的第0天予利妥昔單抗375 mg/m2,21d為1箇週期.治療3～4箇週期(誘導治療結束時)和6箇週期(鞏固治療結束)後評估治療效果、不良反應.結果 11例患者平均年齡72.18歲(55 ～ 83歲).8例閤併其他疾病.10例可評估患者中,誘導治療後總體反應率(ORR)達90％(9/10),5例早期穫得瞭完全反應/未經證實的完全反應(CR/CRu),4例初治瀰漫性大B細胞淋巴瘤( DLBCL)採用GemOx+利妥昔單抗方案,早期ORR達100 ％;4例難治/複髮患者採用GemOx方案,其中3例早期病情得到有效控製.所有患者均未作劑量調整,血液學不良反應可控製,無患者齣現腎髒損害.無疾病進展相關死亡髮生.結論 GemOx加或不加利妥昔單抗方案不良反應可控,耐受良好,是老年B細胞淋巴瘤患者可選的一線治療方案.
목적 탐토길서타빈+오사리박방안(GemOx방안)가혹불가리타석단항치료노년인B세포성림파류적유효성、안전성、내수성.방법 11례경병리활조직검사증실적노년B세포성악성림파류환자균채용길서타빈1000 mg/m2,제1천；오사리박100 mg/m2,제1천,재길서타빈용완후사용；사용리타석단항적환자재매개료정적제0천여리타석단항375 mg/m2,21d위1개주기.치료3～4개주기(유도치료결속시)화6개주기(공고치료결속)후평고치료효과、불량반응.결과 11례환자평균년령72.18세(55 ～ 83세).8례합병기타질병.10례가평고환자중,유도치료후총체반응솔(ORR)체90％(9/10),5례조기획득료완전반응/미경증실적완전반응(CR/CRu),4례초치미만성대B세포림파류( DLBCL)채용GemOx+리타석단항방안,조기ORR체100 ％;4례난치/복발환자채용GemOx방안,기중3례조기병정득도유효공제.소유환자균미작제량조정,혈액학불량반응가공제,무환자출현신장손해.무질병진전상관사망발생.결론 GemOx가혹불가리타석단항방안불량반응가공,내수량호,시노년B세포림파류환자가선적일선치료방안.
Objective To study the efficacy, safety and tolerance of the therapeutic schedule of GemOx±R regimen suitable for elderly patients with B-cell lymphoma. Methods 11 elderly patients with B-cell lymphoma were enrolled in this study, which were diagnosed by biopsy. All the patients were treated according the GemOx ± R therapeutic schedule as described: rituximab (375 mg/m2 on day 0),gemcitabine (1000 mg/m2 on day 1),oxaliplatin (100 mg/m2 on day 1).Treatment response,therapy related toxic and sideeffect were assessed after inductive and consolidated treatment. Results The median age of 11 patients were 72.18 years(range 55-83 years).The overall response rate(ORR) after inductive treatment was 90 ％(9/10).The ORR of 4 DLBCL patients using GemOx+R as initial treatment was 100 ％. GemOx regimen were used for 4 refractory/relapse patients,and 3/4 patients got PR after inductive treatment.No patient got dose adjustment.The hematological toxicity was controllable and nobody got renal function impairment. Conclusions The GemOx ± R regimen is feasible,tolerable,effective for elderly patients with B-cell lymphoma.
